AstraZeneca International - pharmaceutical company, prescription drugs, medicine manufacturers

Go to navigation
Go to content

Reference code :: wf385
Published date :: 09 April 2001
Expired date :: 25 August 2028

First analysis of results from the largest ever study of its type announced today at the 16th annual meeting of the European Association of Urology shows that AstraZeneca's treatment, Casodex™ (bicalutamide) 150mg, cuts the risk of disease progression by almost half in patients with localised or locally advanced prostate cancer.

-

Not signed in

Page tools

Share price

London: 26.95 GBP
New York: 44.82 USD
Stockholm: 310.10 SEK

At 21-Nov-2009 10:43 GMT

Detailed share price

Introduction to AstraZeneca

Our responsibility

We continue to communicate openly on a range of issues, including:

Contact us

Stay in touch

Subscribe via RSS

This website is intended for people seeking information on the AstraZeneca International business. If you are in the US you should visit AstraZeneca US.

We also have national business sites which can be found under our list of AstraZeneca websites.

We also have specific national and international websites designed for patients and healthcare professionals. If you have a question you can contact us.